The introduction of brentuximab vedotin (BV) has significantly impacted treatment outcomes, but the long-term survival trends and predictive factors for this population remain underexplored.<h4>Methods</h4>A total of 1548 patients diagnosed with ALK+ ALCL between 2004 and 2017 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.